LYT-200

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
90 patients (estimated)
Sponsors
PureTech Health
Tags
Monoclonal Antibody, Galectin-9 Protein
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1636
NCT Identifier
NCT05829226

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.